Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Age ≥ 18 years
Able to understand and willing to sign written informed consent
Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
None
Adult patients with histologically or cytologically confirmed malignancy of the head neck area including but not limited to * squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx * not amenable for curative treatment who receive palliative systemic treatment or best supportive care.
Case-only
Prospective
data collection
Other interventionDemography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
Sociodemographic factors
Highest level of education, Employment status, Current professional activity, Professional risk factors, Level of self-sufficiency, Care degree
Treatments
Types of local therapies (surgery, radiotherapy, radiochemotherapy), systemic therapy and therapeutic sequences
Response rates
Response rates
Treatment decision
Physician-reported parameters affecting treatment decision
Click on the lead sponsor to view all of their trials.
AIO-Studien-gGmbH
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
